{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG000","value":"7"}],"title":"PR-Negative"},{"measurements":[{"groupId":"OG000","value":"11"}],"title":"Incomplete Response"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions","groups":[{"description":"-Paclitaxel is administered first, 120 mg/m2 on days 1 and 2 every three weeks for four cycles. Cisplatin is administered at 20 mg/m2 over approximately 30 minutes daily for five days every three weeks for four courses. -The ifosfamide is given last with 1200 mg/m2 daily for five days every three weeks for four cycles.\n\npegfilgrastim\n\ncisplatin\n\nifosfamide\n\npaclitaxel","id":"OG000","title":"Paclitaxel, Ifosfamide, and Cisplatin"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"3 years","title":"Rate of Complete Response","type":"PRIMARY","unitOfMeasure":"Participants"}